Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study

BACKGROUND & AIMS: The CFTR-modulating therapy Elexaftor – Tezacaftor - Ivacaftor (ETI) has been widely prescribed since its approval in 2020 in the European Union. The aim of this study was to methodically evaluate the effects of an ETI treatment on clinical, biochemical data and Pseudomonas co...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, Alexander, Hober, Hannah, Kaiser, Natalie, Ruppel, Renate, Geppert, Annika, Tremel, Christina, Sobel, Julia, Plattner, Erika, Woelfle, Joachim, Hoerning, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160512/
https://www.ncbi.nlm.nih.gov/pubmed/37153441
http://dx.doi.org/10.1016/j.heliyon.2023.e15756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160512/
https://www.ncbi.nlm.nih.gov/pubmed/37153441
http://dx.doi.org/10.1016/j.heliyon.2023.e15756

Ejemplares similares